Pillars of growth
Enoxaparin BIOSIMILAR
Enoxaparin Biosimilar represents an excellent growth opportunity for ROVI considering the significant medical need. Enoxaparin Biosimilar was launched in the UK in March 2018 and is marketed under the brand AROVI®.
Enoxaparin BIOSIMILAR
Enoxaparin Biosimilar represents an excellent growth opportunity for ROVI considering the significant medical need. Enoxaparin Biosimilar was launched in the UK in March 2018 and is marketed under the brand AROVI®.
Research, Development and Innovation
(R&D and I)
R&D and I as an engine for future growth.
Find out +
Contract Manufacturing
High production capacity with four manufacturing plants for pre-filled syringes, oral solids and active principles.
Rovi in figures
276
millions euros2017 Operating Revenue
56
countries
Bemiparin international presencewith 22 international partners
4
plants
for the production of own products and third party products in Spain
28,3 Mn€
Invested in R&D in 2017committed to innovation
6 countries
Direct presencethrough subsidiaries to market Enoxaparin
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.